Top Facebook Posts of 2018
As 2018 comes to a close, we look back on our most popular Facebook posts from throughout the year. All of these stories are the result of Massey’s mission—to save and improve the lives of people affected by cancer. Please join us in this mission and follow us on Facebook to keep up with our activities in the new year.
Thomas Bland is the first stage 4 sarcomatoid kidney cancer patient to show a complete response to immunotherapy. After the standard approach to care failed to slow the spread of Bland's cancer, Massey medical oncologist Dr. Asit Paul decided to try nivolumab. Six months after starting the drug, which is part of a class of immunotherapy agents known as checkpoint inhibitors, Bland showed no signs of cancer and he has now been disease-free for more than two-and-a-half years.
A new clinical trial, which uses the patient’s own tumor to grow immune cells designed to attack cancerous cells in the body, represented the first cell-based immunotherapy performed at Massey. The trial evaluates the effectiveness and safety of this adoptive cell-transfer therapy to treat patients with metastatic melanoma.
Massey researchers, led by Anthony Faber, Ph.D., identified a novel target that can reverse the development of high-risk neuroblastoma. This discovery could lead to new combination therapies for the disease, which typically affects children younger than five years old.
Massey celebrated the groundbreaking of a new outpatient oncology pavilion in June. The pavilion will be part of VCU Health's state-of-the-art outpatient facility located on the downtown medical campus.
Massey physicians were recognized in Richmond magazine's annual Top Docs issue!
Seventy percent of women with the most common type of breast cancer can safely skip chemotherapy, according to the results of a landmark study. TAILORx co-author and physician-researcher Charles Geyer, M.D., who is also Massey's associate director for clinical research, provided insight on why the study's findings are a game changer for breast cancer treatment.
Massey became the first cancer center in the region to use Magseed™, a new device that guides surgeons in locating and removing breast tumors. In the August edition of the WTVR CBS 6 News Buddy Check, Dr. Kandace McGuire, Massey's chief of breast surgery and director of the Breast Cancer Collaborative Care Clinic, discussed the benefits of Magseed™ over traditional methods.
After more than five years of fighting B-cell lymphoma and enduring several failed therapies, Jonathan Newby showed a complete response to the revolutionary treatment that he received at Massey. Newby is the first patient in Virginia to be treated with the FDA-approved CAR T-cell immunotherapy YESCARTA.
We broadcast live from Richmond International Airport where Joseph Fahrenbach and his wife Ashley reunited with Joe’s old military dog, Fuli, who he had not seen since 2015! Fuli retired from service, but Joe was battling leukemia and was not in a position to adopt him. Thankfully, a bone marrow donor in Germany was a match and Joe underwent a life-saving stem cell transplant at Massey in January. With his health improving, Mission K9 Rescue fufilled their mission and reunited these two old friends!
We announced that commercially approved CAR T-cell therapies were available in Virginia. Massey is currently offering YESCARTA™ by Kite Pharma for adults with recurrent or refractory B-cell lymphomas, and we will soon partner with Children's Hospital of Richmond at VCU to offer KYMRIAH™ by Novartis for children and young adults with recurrent or refractory B-cell acute lymphoblastic leukemia. Watch as Dr. McCarty explains this exciting form of immunotherapy and how we have expanded the state's largest bone marrow transplant program to be able to offer the latest FDA-approved and experimental cellular therapies.